Drug Trial Radar · NCT05540860
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
76
Actual
Start
Oct 24, 2022
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1Drug
Sevasemten is administered orally once per day
Sevasemten Dose 2Drug
Sevasemten is administered orally once per day
Sevasemten Dose 3Drug
Sevasemten is administered orally once per day
Sevasemten Dose 4Drug
Sevasemten is administered orally once per day
Sevasemten Dose 5Drug
Sevasemten is administered orally once per day
PlaceboDrug
Placebo is administered orally once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events during treatment with sevasemten or placeboTime frame: 48 months
- Severity of adverse events during treatment with sevasemten or placeboTime frame: 48 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
UCLA Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
University of Florida
Gainesville, Florida
Rare Disease Research
Atlanta, Georgia
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Cincinnati Children's Hospital
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Cook Children's Medical Center
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.